About Darmiyan
Darmiyan is a medical AI company focused on revolutionizing brain health diagnostics through advanced imaging analysis. The company's name, a Persian word meaning 'in-between,' reflects its focus on the space between brain cells and the critical period between normal health and neurodegenerative disease. Founded by a team of neuroscientists, data scientists, healthcare experts, and patient advocates, Darmiyan leverages over 40 years of cutting-edge neuroscience research combined with advanced medical image processing and machine learning to address early detection of neurodegenerative diseases. The company's patented core technology, DarmiScope, functions as the first virtual microscope of the human brain, offering unprecedented precision in quantifying cellular-level changes within every voxel (3D pixel) of a brain MRI scan. Their flagship product, BrainSee, received FDA De Novo approval in January 2024 and is the first FDA-approved medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). BrainSee combines a patient's brain MRI with cognitive test scores to generate a score between 0 and 100, helping doctors determine the likelihood of progression to Alzheimer's dementia with approximately 90% accuracy over a 5-year period. Darmiyan serves healthcare providers, pharmaceutical companies, and clinical researchers working to advance brain health and wellness. The company aims to provide an à la carte menu of brain tests developed with four pillars of excellence: high accuracy, non-invasiveness, seamless integration, and high accessibility worldwide. Their technology has been validated through blind testing of 411 cases with 5-year follow-up and by independent third-party investigators in the US and Canada.
Mission & Story
Mission
Our mission is to leverage 40 years of cutting edge neuroscience research combined with advanced medical image processing and advanced ML/AI to address the biggest healthcare challenge of our time: detecting neurodegenerative disease at early stages when treatments matter.
Founding Story
Founded by CEO Padideh Kamali-Zare, PhD and Chief Medical & Technology Officer Kaveh Vejdani, MD, along with co-founder Thomas Liebmann, PhD. The company draws on over four decades of pioneering brain research to develop technology that focuses on the space between brain cells, grading the health of that space to help people understand what's happening between normal health and neurodegenerative disease.
Clinical Focus
Medical conditions and clinical areas addressed by Darmiyan.
Who It Serves
Milestones & Awards
Recent Milestones
FDA De Novo approval for BrainSee (January 2024). FDA Breakthrough Device Designation (May 2021). Validation by third-party investigators (2020). $6M funding round led by Eisai (2020).
Awards & Recognition
Fortune 40 under 40 (CEO, 2020). UCSF Award finalist - hospital diagnostics category (2021). CABHI 2019 Innovation Award. Amgen-QB3/MBC Biolabs Golden Ticket Award (2017). Y-Combinator S17 graduate. SkyDeck UC Berkeley graduate. Finalist for AI for Good $500K prize (2018). Top 25 women leaders in biotech (CEO, 2021).
Key Partnerships
Company Details
- Founded
- 2017
- Headquarters
- San Francisco, CA, USA
- Employees
- 1-10
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 189 →
A2z Radiology Ai
AI platform that triages urgent abdomen-pelvis CT findings and prioritizes flagged studies in radiology worklists.
Adas3D Medical S.L
11-50 employees
Adas3D Medical develops medical imaging software that extracts key clinical information from cardiac MRI and CT scans for electrophysiologists. The software helps plan, guide, and monitor catheter ablation procedures by visualizing and quantifying fibrotic tissue in the heart.
AEYE Health
11-50 employees
AEYE Health provides FDA-cleared autonomous AI diagnostic screening for diabetic retinopathy and other eye diseases using retinal images. Their point-of-care solution enables primary care physicians to screen and diagnose patients instantly with portable or desktop cameras.
Agfa HealthCare N.V.
AGFA HealthCare provides enterprise imaging platforms that unify medical imaging across specialties. The company delivers PACS, vendor neutral archives, AI-powered workflow orchestration, and cloud-based imaging solutions to hospitals and healthcare systems worldwide.
AI4MedImaging Medical Solutions
AI4MedImaging provides AI-powered medical imaging solutions distributed through aycan Medical Systems in the Americas. Their flagship product, AI4CMR, is software as a medical device (SaMD) that automates the interpretation of cardiac magnetic resonance imaging using artificial intelligence.
Aidence
Aidence, now part of DeepHealth, develops AI-powered clinical applications for radiology and medical imaging. The company specializes in lung nodule detection, classification, and patient management solutions that empower radiologists and physicians in interpreting medical images.
Aidoc
growth · 350 employees
Aidoc empowers health systems to improve patient outcomes and operations with enterprise-grade healthcare AI.
Aikenist Technologies Pvt Ltd
21-100 employees
Aikenist Technologies is a MedTech company specializing in advanced AI-driven solutions for radiology imaging. Their offerings include an FDA-approved AI PACS and RIS with integrated viewer, appointment scheduling, billing modules, and AI tools for stroke, oncology, and neuro detection.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.